Dr Sajid and colleagues from England systematically analyzed the prospective randomized controlled trials on the effectiveness of diltiazem and glyceryltrinitrate for the pharmacological management of chronic anal fissures.
|Glyceryltrinitrate was associated with higher side effects rates|
|International Journal of Colorectal Disease|
The team selected prospective randomized controlled trials on the effectiveness of diltiazem for the management of chronic anal fissures.
The researchers selected and analyzed the trials according to specific criteria to generate summative data.
The researchers retrieved 5 studies encompassing 263 patients with chronic anal fissures from the electronic databases.
The team found that only 2 randomized controlled trials on 103 patients qualified for the meta-analysis.
There were 53 patients in the diltiazem group, and 50 patients in the glyceryltrinitrate group.
Both diltiazem and glyceryltrinitrate were equally effective for the treatment of chronic anal fissure.
The research team found, however, that there was significant heterogeneity between the trials.
Glyceryltrinitrate was associated with higher side effects rate, such as headaches, as compared to diltiazem.
There was no statistically significant recurrence rate of chronic anal fissures between 2 pharmacotherapies.
Dr Sajid's team concluded, "Both diltiazem and glyceryltrinitrate are equally effective and can be used for the management of chronic anal fissures."
"However, glyceryltrinitrate is associated with a higher rate of side effects, and it should be replaced by diltiazem."
"The recurrence rate of chronic anal fissure after the use of both pharmacotherapies is equal."